Julie A. Frearson

3.8k total citations · 1 hit paper
43 papers, 2.2k citations indexed

About

Julie A. Frearson is a scholar working on Molecular Biology, Epidemiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Julie A. Frearson has authored 43 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 23 papers in Epidemiology and 18 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Julie A. Frearson's work include Trypanosoma species research and implications (23 papers), Research on Leishmaniasis Studies (15 papers) and Biochemical and Molecular Research (9 papers). Julie A. Frearson is often cited by papers focused on Trypanosoma species research and implications (23 papers), Research on Leishmaniasis Studies (15 papers) and Biochemical and Molecular Research (9 papers). Julie A. Frearson collaborates with scholars based in United Kingdom, Norway and United States. Julie A. Frearson's co-authors include Paul G. Wyatt, Ian H. Gilbert, Denis R. Alexander, Ruth Brenk, Alan H. Fairlamb, Alessandro Schipani, Iain T. Collie, Emma Shanks, Deuan C. Jones and Irene Hallyburton and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Experimental Medicine and PLoS ONE.

In The Last Decade

Julie A. Frearson

43 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases

2007 482 citations Ruth Brenk, Ian H. Gilbert et al. ChemMedChem profile →

Peers

Countries citing papers authored by Julie A. Frearson

Since Specialization

Citations

This map shows the geographic impact of Julie A. Frearson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie A. Frearson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie A. Frearson more than expected).

Fields of papers citing papers by Julie A. Frearson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie A. Frearson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie A. Frearson. The network helps show where Julie A. Frearson may publish in the future.

Co-authorship network of co-authors of Julie A. Frearson

This figure shows the co-authorship network connecting the top 25 collaborators of Julie A. Frearson. A scholar is included among the top collaborators of Julie A. Frearson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie A. Frearson. Julie A. Frearson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N -Myristoyltransferase Inhibitors 2018 ·Journal of Medicinal Chemistry ·Justin R. Harrison, Stephen Brand, Victoria Smith, David A. Robinson, Stephen Thompson, (unknown), Kenneth Davies, N. Yi Mok, Leah S. Torrie, Iain T. Collie, Irene Hallyburton, Suzanne Norval, Frederick R. C. Simeons, Laste Stojanovski, Julie A. Frearson, Ruth Brenk, Paul G. Wyatt, Ian H. Gilbert, Kevin D. Read	46
2	Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors 2017 ·Journal of Medicinal Chemistry ·Tracy Bayliss, David A. Robinson, Victoria Smith, Stephen Brand, Stuart P. McElroy, Leah S. Torrie, Chido Mpamhanga, Suzanne Norval, Laste Stojanovski, Ruth Brenk, Julie A. Frearson, Kevin D. Read, Ian H. Gilbert, Paul G. Wyatt	16
3	Screening a protein kinase inhibitor library against Plasmodium falciparum 2017 ·Malaria Journal ·Irene Hallyburton, Raffaella Grimaldi, Andrew Woodland, Beatriz Baragaña, Torsten Luksch, Daniel Spinks, (unknown), Didier Leroy, David Waterson, Alan H. Fairlamb, Paul G. Wyatt, Ian H. Gilbert, Julie A. Frearson	16
4	Comparison of a High-Throughput High-Content Intracellular Leishmania donovani Assay with an Axenic Amastigote Assay 2013 ·Antimicrobial Agents and Chemotherapy ·Manu De Rycker, Irene Hallyburton, John Thomas, Lorna Campbell, Susan Wyllie, Dhananjay Joshi, Scott Cameron, Ian H. Gilbert, Paul G. Wyatt, Julie A. Frearson, Alan H. Fairlamb, David W. Gray	108
5	From On‐Target to Off‐Target Activity: Identification and Optimisation of Trypanosoma brucei GSK3 Inhibitors and Their Characterisation as Anti‐Trypanosoma brucei Drug Discovery Lead Molecules 2013 ·ChemMedChem ·Andrew Woodland, Raffaella Grimaldi, Torsten Luksch, Laura A. T. Cleghorn, Kayode K. Ojo, Wesley C. Van Voorhis, Ruth Brenk, Julie A. Frearson, Ian H. Gilbert, Paul G. Wyatt	22
6	Optimizing the use of CROs by academia and small companies 2013 ·Nature Reviews Drug Discovery ·Rachel Lane, Lauren G. Friedman, Curtis T. Keith, Steven P. Braithwaite, Julie A. Frearson, (unknown), Frank M. Longo, Lorenzo M. Refolo, D. Martin Watterson, Katya Tsaioun, Diana W. Shineman, Howard Fillit	2
7	Assessment of Pseudomonas aeruginosa N5,N10-Methylenetetrahydrofolate Dehydrogenase - Cyclohydrolase as a Potential Antibacterial Drug Target 2012 ·PLoS ONE ·(unknown), Mary Gardiner, (unknown), Stuart P. McElroy, Daniel James, Julie A. Frearson, David W. Gray, William N. Hunter	18
8	Design, Synthesis and Biological Evaluation of Trypanosoma brucei Trypanothione Synthetase Inhibitors 2011 ·ChemMedChem ·Daniel Spinks, Leah S. Torrie, Stephen Thompson, Justin R. Harrison, Julie A. Frearson, Kevin D. Read, Alan H. Fairlamb, Paul G. Wyatt, Ian H. Gilbert	36
9	Optimisation of the Anti‐Trypanosoma brucei Activity of the Opioid Agonist U50488 2011 ·ChemMedChem ·Victoria Smith, Laura A. T. Cleghorn, Andrew Woodland, Daniel Spinks, Irene Hallyburton, Iain T. Collie, N. Yi Mok, Suzanne Norval, Ruth Brenk, Alan H. Fairlamb, Julie A. Frearson, Kevin D. Read, Ian H. Gilbert, Paul G. Wyatt	6
10	Finding New Hits in Neglected Disease Projects: Target or Phenotypic Based Screening? 2011 ·Current Topics in Medicinal Chemistry ·Ian H. Gilbert, Didier Leroy, Julie A. Frearson	19
11	Design, Synthesis and Biological Evaluation of Novel Inhibitors of Trypanosoma brucei Pteridine Reductase 1 2010 ·ChemMedChem ·Daniel Spinks, Han B. Ong, Chidochangu P. Mpamhanga, Emma Shanks, David A. Robinson, Iain T. Collie, Kevin D. Read, Julie A. Frearson, Paul G. Wyatt, Ruth Brenk, Alan H. Fairlamb, Ian H. Gilbert	32
12	Nuclear DBF-2-related Kinases Are Essential Regulators of Cytokinesis in Bloodstream Stage Trypanosoma brucei 2010 ·Journal of Biological Chemistry ·Jiangtao Ma, Corinna Benz, Raffaella Grimaldi, (unknown), Paul G. Wyatt, Julie A. Frearson, Tansy C. Hammarton	29
13	Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis 2010 ·Biochemical Pharmacology ·Deuan C. Jones, Irene Hallyburton, Laste Stojanovski, Kevin D. Read, Julie A. Frearson, Alan H. Fairlamb	56
14	Acetazolamide-based fungal chitinase inhibitors 2010 ·Bioorganic & Medicinal Chemistry ·Alexander W. Schüttelkopf, (unknown), D.E. Blair, Julie A. Frearson, Daan M. F. van Aalten, Ian H. Gilbert	42
15	HTS and hit finding in academia – from chemical genomics to drug discovery 2009 ·Drug Discovery Today ·Julie A. Frearson, Iain T. Collie	64
16	Development and validation of a cytochrome c-coupled assay for pteridine reductase 1 and dihydrofolate reductase 2009 ·Analytical Biochemistry ·Emma Shanks, Han B. Ong, David A. Robinson, Stephen Thompson, Natasha Sienkiewicz, Alan H. Fairlamb, Julie A. Frearson	18
17	Synthesis and Evaluation of 1‐(1‐(Benzo[b]thiophen‐2‐yl)cyclohexyl)piperidine (BTCP) Analogues as Inhibitors of Trypanothione Reductase 2009 ·ChemMedChem ·Stephen Patterson, Deuan C. Jones, Emma Shanks, Julie A. Frearson, Ian H. Gilbert, Paul G. Wyatt, Alan H. Fairlamb	42
18	Target assessment for antiparasitic drug discovery 2007 ·Trends in Parasitology ·Julie A. Frearson, Paul G. Wyatt, Ian H. Gilbert, Alan H. Fairlamb	108
19	The role of phosphotyrosine phosphatases in haematopoietic cell signal transduction 1997 ·BioEssays ·Julie A. Frearson, Denis R. Alexander	59
20	A tyrosine‐phosphorylated 110–120‐kDa protein associates with the C‐terminal SH2 domain of phosphotyrosine phosphatase‐1D in T cell receptor‐stimulated T cells 1996 ·European Journal of Immunology ·Julie A. Frearson, Taolin Yi, Denis R. Alexander	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact